Suppr超能文献

前列腺素在介导血管紧张素转换酶抑制剂及其他抗高血压药物作用中的角色。

The role of prostaglandins in mediating the effects of angiotensin converting enzyme inhibitors and other antihypertensive drugs.

作者信息

Swartz S L

机构信息

Department of Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, MA 02115.

出版信息

Cardiovasc Drugs Ther. 1987;1(1):39-43. doi: 10.1007/BF02125831.

Abstract

This review considers the hypothesis that angiotensin converting enzyme (ACE) inhibitors and other antihypertensive drugs may reduce blood pressure by altering the balance of vasoconstrictor and vasodilator hormones. Most cases of essential hypertension are characterized by increased vascular resistance. Since vascular resistance can be viewed as a net balance of offsetting vasoconstrictor and vasodilator neurohumoral forces, and since angiotensin II and norepinephrine can stimulate the synthesis of vasodilator prostaglandins that can in turn counteract peripheral vasoconstriction, we measured changes in vasoconstrictor (angiotensin II) and vasodilator (PGE2) hormones after giving different antihypertensive drugs. We found that the sulfhydryl containing converting enzyme inhibitor captopril increased vasodilator prostaglandin production (PGE2-metabolite) both acutely and chronically. This increase in PGE2-metabolite was not seen with the non-sulfhydryl converting enzyme inhibitor, enalapril.

摘要

本综述探讨了一种假说,即血管紧张素转换酶(ACE)抑制剂及其他抗高血压药物可能通过改变血管收缩激素和血管舒张激素的平衡来降低血压。大多数原发性高血压病例的特征是血管阻力增加。由于血管阻力可被视为相互抵消的血管收缩和血管舒张神经体液力量的净平衡,且由于血管紧张素II和去甲肾上腺素可刺激血管舒张前列腺素的合成,而后者又可反过来抵消外周血管收缩,因此我们在给予不同抗高血压药物后测量了血管收缩激素(血管紧张素II)和血管舒张激素(前列腺素E2)的变化。我们发现,含巯基的转换酶抑制剂卡托普利可急性和慢性地增加血管舒张前列腺素的生成(前列腺素E2代谢物)。非巯基转换酶抑制剂依那普利则未出现前列腺素E2代谢物的这种增加。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验